Protalix Biotherapeutics, Inc.
(NYSE Amex Equities : PLX)

( )
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Interested in Binary Options?
We'll teach you the best ways to trade binaries.
100% secure: your email is never shared, and you may opt out at any time.
...
Health Services » Servicestothe Health Industry
symbolcompany%chnglast%shortavg$volume
DGXQuest Diagnostics, Inc. 0.14%117.984.3%$163.44m
LHLaboratory Corp. of America Holdings 0.50%173.462.4%$143.96m
SYNHSyneos Health, Inc. -0.12%58.080.0%$64.28m
NRCNational Research Corp. -1.79%57.010.0%$2.60m
IDXGInterpace Biosciences, Inc. -12.58%5.5622.8%$2.41m
AMEHApollo Medical Holdings, Inc. -2.05%16.250.0%$1.95m
PLXProtalix Biotherapeutics, Inc. -1.64%3.6026.0%$0.71m
PMDPsychemedics Corp. -2.18%5.380.7%$0.14m
BASIBioanalytical Systems, Inc. -1.69%4.960.2%$0.09m

Company Profile

Protalix Biotherapeutics, Inc. engages in the development, production, and commercialization of recombinant therapeutic proteins based on plant cell based expression system. Its products include Alidornase alfa and OPRX-106. The company was by Yoseph Shaaltiel in 1993 and is headquartered in Karmiel, Israel.